AVET LIFESCIENCES
GenericsAVET LIFESCIENCES is a generic drug manufacturer focused on Infectious Disease, Oncology, Dermatology.
AVET LIFESCIENCES's Key Drugs
AVET LIFESCIENCES's core commercial portfolio centers on METOCLOPRAMIDE, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.
AVET LIFESCIENCES's Recent FDA Approvals
New NDA/BLA approvals for AVET LIFESCIENCES over the last two years — novel drugs only, excluding generics and label supplements.
AVET LIFESCIENCES's Therapeutic Areas
AVET LIFESCIENCES's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVET LIFESCIENCES's Top Competitors
AVET LIFESCIENCES's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVET LIFESCIENCES Pipeline Snapshot
Active clinical trials for AVET LIFESCIENCES across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • METOCLOPRAMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1977-03-07
- Latest
- 2026-06-05
- Applications
- 39